GLP-1 receptor agonists have known GI side effects (nausea, vomiting, constipation, diarrhea) that are dose-dependent and generally manageable but affect adherence
Various transcription factors are involved in GPX4 transcriptional regulation
The anti-fibrotic actions of relaxin are mediated through AT(2) R-associated protein phosphatases via RXFP1-AT(2) R functional crosstalk in human cardiac myofibroblasts
Wegovy works by mimicking a hormone that targets areas of the brain involved in regulating appetite and food intake
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health
Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, has seen explosive uptake due to its efficacy in glycemic control, weight loss and cardiometabolic risk reduction, driving multibillion-dollar revenues for originator companies Novo Nordisk (maker of semaglutide products Ozempic and Wegovy) and Eli Lilly (the pharma giant behind the tirzepatide products Mounjaro and Zepbound)
